GSK-971086

A drug developed for the treatment of chronic pain

GSK-971086 is a chemical compound that was developed as a potential treatment for chronic pain. It is a member of a class of drugs known as ion channel modulators, specifically targeting the sodium channels in the nervous system.

Mechanism of Action

GSK-971086 functions by modulating the activity of sodium channels, which are crucial for the generation and propagation of action potentials in neurons. By altering the function of these channels, GSK-971086 can reduce the excitability of neurons, thereby potentially alleviating pain.

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na⁺) through a cell's plasma membrane. These channels are essential for the rapid depolarization phase of the action potential. GSK-971086 is believed to selectively target certain subtypes of sodium channels that are involved in pain signaling pathways.

Development and Research

GSK-971086 was developed by GlaxoSmithKline, a major pharmaceutical company, as part of their research into novel pain management therapies. The compound was investigated for its efficacy in treating various forms of chronic pain, including neuropathic pain and inflammatory pain.

Research into GSK-971086 involved preclinical studies using animal models to assess its pharmacokinetics, pharmacodynamics, and safety profile. These studies aimed to determine the optimal dosing regimen and to identify any potential side effects associated with the drug.

Potential Applications

The primary application of GSK-971086 is in the management of chronic pain conditions. Chronic pain is a significant medical issue that affects millions of people worldwide, often leading to reduced quality of life and increased healthcare costs. Traditional pain management strategies, such as opioids and non-steroidal anti-inflammatory drugs (NSAIDs), have limitations and potential side effects, making the development of new therapies like GSK-971086 important.

Challenges and Considerations

While GSK-971086 shows promise as a pain management therapy, there are several challenges associated with its development. These include ensuring the selectivity of the drug for specific sodium channel subtypes to minimize off-target effects, as well as establishing a favorable safety and efficacy profile in clinical trials.

Related Pages

• Chronic pain
• Sodium channel
• Neuropathic pain
• GlaxoSmithKline

Chemical structure of GSK-971086